NCT06739278View on ClinicalTrials.gov

Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease

Not yet recruitingOBSERVATIONAL
Enrollment

119

Participants

Timeline

Start Date

December 20, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

January 31, 2025

Conditions
Crohn Disease
Trial Locations (1)

325000

The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Wenzhou Medical University

OTHER

NCT06739278 - Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease | Biotech Hunter | Biotech Hunter